TL;DR: A new 2026 dermatology review put AP31, a cosmetic anti-inflammatory micropeptide, into the conversation around skin laxity after GLP-1-associated weight loss. The clearest effect-size data come from the full AP31 clinical paper: a 16-week, single-arm study in 38 women using a finished AP31 0.4% face-and-neck cream twice daily. At week 16, clinician-graded lower-face endpoints improved modestly: nasolabial folds by 11%, global lift by 10%, and jawline sagging by 9%. That is interesting, but it is not the same as a randomized, placebo-controlled proof of lifting.
Bottom line for your skin: AP31 is a plausible peptide to watch for firmer-looking skin and lower-face contour support. The honest read is “promising finished-formula evidence,” not “topical facelift,” not “proven GLP-1 face treatment,” and not proof that every peptide serum will do this.
The Study
The newest PubMed signal is a 2026 review about AP31 as a possible cosmetic adjunct for laxity concerns in people using GLP-1 receptor agonists. For actual human effect sizes, the stronger source is the full AP31 paper published in Journal of Drugs in Dermatology. That clinical study was prospective, single-arm, single-center, and ran for 16 weeks. Participants were women aged 40 to 65 with Fitzpatrick skin types I-IV and mild-to-moderate jawline sagging, wrinkles, and fine lines. Everyone used the same AP31 0.4% finished cream twice daily; there was no placebo or comparator arm.
Key Outcomes / Results
| Outcome | Reported result | How to read it |
|---|---|---|
| Study design | 38 women; 16 weeks; single-arm finished cream study | Useful early human evidence, but weaker than a randomized placebo-controlled trial. |
| Nasolabial folds | 11% mean improvement at week 16 | The largest lower-face clinician-score signal; likely subtle, not dramatic. |
| Global lift | 10% mean improvement at week 16 | Supports careful “firmer-looking” or “lifted appearance” language for the tested product. |
| Jawline sagging | 9% mean improvement at week 16 | A lower-face contour signal, but no control group means time, routine, and expectation are not separated out. |
| Broad clinical grading | All 15 clinician-graded parameters improved at weeks 12 and 16; P<0.01 | Broad directionally positive signal, but the design makes the exact product-attributable effect uncertain. |
| Self-assessment | 94% reported firmer, more elastic skin at week 2; 92% noted jawline/facial contour improvement at week 16 | Helpful for consumer perception, but subjective and not blinded against placebo. |
| Tolerability | No product-related adverse events reported; no significant worsening in edema, erythema, dryness, burning, stinging, itching, or tightness | The tolerability signal is reassuring for this formula over 16 weeks. |
Dermatologist/Researcher Interpretation
The most important thing to understand is the design. This was not a trial where half the participants used AP31 and half used placebo. It was a before-and-after study of one finished product. That means the results can show that people improved over time while using the cream, but they cannot fully prove how much of the change came from AP31 itself, the vehicle, sunscreen use, adherence to a routine, regression to the mean, or expectation.
The lower-face results are still worth paying attention to because they measured clinically visible endpoints: jawline sagging, global lift, and nasolabial folds. Those are closer to what a person sees in the mirror than a lab-only collagen marker. The size of the effect, however, is modest. A 9-11% clinician-score improvement sounds like a softening or mild contour improvement, not a procedure-like lift.
The preclinical biology makes the ingredient plausible. AP31 reduced inflammatory mediators in cell models and increased extracellular-matrix-related markers such as procollagen, elastin, decorin, fibronectin, and hyaluronic acid in lab systems. That supports a rationale for firmness and barrier-related benefits. But lab biology should sit behind the human result, not replace it.
For GLP-1-associated weight-loss skin changes, the evidence is even earlier. The 2026 review frames AP31 as relevant because inflammation, extracellular matrix quality, and visible laxity matter after rapid body-composition change. But the AP31 clinical study was not specifically a GLP-1 weight-loss trial. A fair claim is that AP31 may be a reasonable cosmetic ingredient to study for this concern. A stronger claim, such as “proven for GLP-1 face,” needs a dedicated randomized trial.
What this means for product claims
Reasonable: a finished AP31 0.4% cream showed modest clinician-graded improvements in lower-face appearance, fine lines/wrinkles, smoothness, tone, and hyperpigmentation over 16 weeks in a small single-arm study. Too far: AP31 is proven to reverse skin laxity from weight loss, rebuild the face, replace procedures, or work the same way in every formula.
Key limitations
- No placebo or comparator arm, so product-attributable effect size is uncertain.
- Small study population: 38 women in the per-protocol analysis.
- The evidence applies to the tested finished cream, not AP31 in every possible serum, cream, or concentration.
- The GLP-1/weight-loss application is a rationale from the newer review, not a dedicated GLP-1 patient trial.
- The study was supported by Kenvue Brands LLC, and several authors were Kenvue employees or consultants.
References: Lisante TA, Green B, Hubert K, et al. A Novel Cosmetic Anti-inflammatory Peptide With Firming and Lifting Benefits: The Potential for Adjunctive Care for Skin Laxity Associated With Weight Loss. Dermatologic Surgery. 2026. doi: 10.1097/DSS.0000000000005181. PMID: 42210882. Edison BL, Parsa R, Dufort M, et al. Acetyl Dipeptide-31 Amide: A Novel Cosmetic Anti-Inflammatory Peptide That Demonstrates Anti-Aging, Firming, and Lifting Benefits. Journal of Drugs in Dermatology. 2025;24(1):23-33. doi: 10.36849/JDD.8786. PMID: 39761149.